Scenesse for EPP is ready for Prime Time
Scenesse is a medicine that can give sufferers of Erythropoietic Protoporphyria (EPP) a new lease on life. The FDA approval of Scenesse for EPP in October 2019 was a watershed moment for US patients with this devastating disease. It has been a long time coming and it is now ready for use. The path to insurance approval is long and arduous but doable. Because it was just approved by the FDA, it will require a lot of flips and twists to get it to the patients who need it.